Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Dimesylate, Lis-dexamfetamine
2. Dimesylate, Lisdexamfetamine
3. Elvanse
4. Lis Dexamfetamine Dimesylate
5. Lis-dexamfetamine Dimesylate
6. Lisdexamfetamine
7. Nrp 104
8. Nrp-104
9. Nrp104
10. Vyvanse
1. Vyvanse
2. 608137-33-3
3. Nrp-104
4. Lisdexamfetamine Mesilate
5. Spd489
6. Tyvense
7. Nrp104
8. Spd-489
9. Lisdexamfetamine Dimesylate [usan]
10. Lisdexamfetamine Dimesilate
11. Sjt761gegs
12. Lisdexamphetamine Dimesilate
13. L-lysine-d-amphetamine Dimesylate
14. Lisdexamfetamine Dimethanesulfonate
15. (2s)-2,6-diamino-n-[(1s)-1-methyl-2-phenylethyl]hexanamide Dimethanesulfonate
16. Lis-dexamfetamine Dimesylate
17. Lisdexamfetamine Mesilate (jan)
18. Lisdexamfetamine Dimesylate (usan)
19. Lisdexamfetamine Mesylate
20. Nrp 104
21. Lisdexamfetamine Mesilate [jan]
22. (2s)-2,6-diamino-n-[(2s)-1-phenylpropan-2-yl]hexanamide;methanesulfonic Acid
23. Unii-sjt761gegs
24. Venvanse
25. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulfonate
26. Lys-amp
27. Spd 489
28. Lys-d-amp
29. Elvanse (tn)
30. Vyvanse (tn)
31. Schembl678421
32. Chembl1201178
33. Dtxsid60209653
34. Lisdexamfetamine Dimesylate Solution
35. Bcp24044
36. Akos030254940
37. Lisdexamfetamine Mesilate [mart.]
38. Ldx
39. Lisdexamfetamine Mesilate [who-dd]
40. Lisdexamfetamine Dimesylate [vandf]
41. D04747
42. Lisdexamfetamine Dimethanesulfonate [mi]
43. Lisdexamfetamine Dimesylate [orange Book]
44. 137l333
45. Q27289243
46. (2s)-2,6-diamino-n-((1s)-1-methyl-2-phenylethyl)hexanamide Dimethanesulphonate
47. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulfonate
48. Hexanamide, 2,6-diamino-n-((1s)-1-methyl-2-phenylethyl), (2s), Dimethanesulphonate
49. Ldx;lisdexamfetamine Mesilate;lisdexamfetamine Mesylate;nrp 104;nrp-104;spd 489
50. Lisdexamfetamine Dimesylate Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 455.6 g/mol |
|---|---|
| Molecular Formula | C17H33N3O7S2 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 455.17599275 g/mol |
| Monoisotopic Mass | 455.17599275 g/mol |
| Topological Polar Surface Area | 207 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 344 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 4 | |
|---|---|
| Drug Name | Lisdexamfetamine dimesylate |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Amneal Pharms; Roxane |
| 2 of 4 | |
|---|---|
| Drug Name | Vyvanse |
| PubMed Health | Amphetamine (By mouth) |
| Drug Classes | Amphetamine |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
| Market Status | Prescription |
| Company | Shire Development |
| 3 of 4 | |
|---|---|
| Drug Name | Lisdexamfetamine dimesylate |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 70mg; 20mg |
| Market Status | Tentative Approval |
| Company | Mylan Pharms; Amneal Pharms; Roxane |
| 4 of 4 | |
|---|---|
| Drug Name | Vyvanse |
| PubMed Health | Amphetamine (By mouth) |
| Drug Classes | Amphetamine |
| Drug Label | Vyvanse (lisdexamfetamine dimesylate), a CNS stimulant,isa capsule for once-a-day oral administration. The chemical designation for lisdexamfetamine dimesylate is (2S)-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl] hexanamide dimethanesulfonate.... |
| Active Ingredient | Lisdexamfetamine dimesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 30mg; 50mg; 60mg; 40mg; 20mg; 70mg |
| Market Status | Prescription |
| Company | Shire Development |
Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
NDC Package Code : 49812-0186
Start Marketing Date : 2012-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
NDC Package Code : 51634-2058
Start Marketing Date : 2021-12-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42282
Submission : 2025-07-11
Status : Active
Type : II
| Available Reg Filing : BR |
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-024
Start Marketing Date : 2024-10-28
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-28
Pay. Date : 2020-01-21
DMF Number : 22442
Submission : 2009-01-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-11-21
Pay. Date : 2023-10-12
DMF Number : 38874
Submission : 2023-10-20
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2021-12-30
Pay. Date : 2021-11-18
DMF Number : 35645
Submission : 2021-11-23
Status : Active
Type : II
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42282
Submission : 2025-07-11
Status : Active
Type : II
USDMF
GDUFA
DMF Review : Complete
Rev. Date : 2025-04-21
Pay. Date : 2025-04-08
DMF Number : 38667
Submission : 2023-08-03
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36325
Submission : 2021-10-25
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20103
Submission : 2006-12-29
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-07-02
Pay. Date : 2018-05-22
DMF Number : 32289
Submission : 2018-05-18
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2020-07-28
Pay. Date : 2020-06-03
DMF Number : 34823
Submission : 2020-05-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32210
Submission : 2017-11-22
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare...
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
About the Company : Noramco, founded in 1979, specializes in developing and manufacturing APIs for opioid and non-opioid products. It excels in controlled substance development, offering supply-chain ...
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
About the Company : Supriya Lifescience Limited, established in 1987 and headquartered in Mumbai, is a globally recognized, technology-driven manufacturer of APIs, CDMO, and formulations. Its faciliti...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform delivering products and services across the full molecule lifecycle, from development to commercialization. With strong expe...
About the Company : Temad Co., established in 1997, is one of Iran's largest API producers and an innovative manufacturer of narcotic and non-narcotic products in the Middle East. It complies with Ira...
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
About the Company : Malladi Drugs & Pharmaceuticals Ltd, founded in 1980 by Mr. M L N Sastry, is a leader in manufacturing ephedrine and pseudoephedrine salts. It is now the top API manufacturer in th...
About the Company : Since 1962, MOEHS has produced high-quality Active Pharmaceutical Ingredients (APIs) for the global market. With decades of technical expertise, Moehs Group delivers pharmaceutical...
Siegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.
About the Company : Siegfried is a global Contract Development and Manufacturing Organization providing integrated services for pharmaceutical ingredients & finished dosage forms. With 13 production s...
About the Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expertise, is located on a...

About the Company : Chr. Olesen Synthesis is a Danish manufacturer of APIs and advanced intermediates. Chr. Olesen Synthesis was established in 2012 after the Chr. Olesen Group acquisition of the mult...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 30, 2025
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Strengthens ADHD Portfolio with FDA Approval for Lisdexamfetamine Dimesylate
Details : FDA approved Lisdexamfetamine Dimesylate Capsules, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 30, 2025
Details:
FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2024
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Announces FDA Approval for ADHD Treatment
Details : FDA approved Lisdexamfetamine Dimesylate Tablets, a bioequivalent and therapeutically equivalent to the reference listed drug, Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 17, 2024
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Centanafadine is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Centanafadine,Methylphenidate,Lisdexamfetamine Dimesylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Centanafadine,Methylphenidate,Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
Details : Centanafadine is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 02, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lisdexamfetamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Lisdexamfetamine Dimesylate
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lisdexamfetamine Dimesylate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lisdexamfetamine 70 mg vs Elvanse® 70 mg Bioavailability Under Fasting In Healthy Adults
Details : Lisdexamfetamine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 06, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate
Details : Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 06, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 31, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lisdexamfetamine Dimesylate Capsules are a federally controlled substance (CII) used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other indications and currently are on the FDA's drug shortage list.
Product Name : Vyvanse-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bulimia Nervosa.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Controlled Substance
Sponsor: Nova Scotia Health Authority
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 12, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Nova Scotia Health Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Lisdexamfetamine for Adults With Bulimia Nervosa
Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bulimia Nervosa.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 12, 2018

Details:
Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Controlled Substance
Sponsor: SHIRE PLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2017

Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 09, 2017

Details:
Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Lisdexamfetamine Dimesylate,Guanfacine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Controlled Substance
Sponsor: SHIRE PLC
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2017

Lead Product(s) : Lisdexamfetamine Dimesylate,Guanfacine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents
Details : Lisdexamfetamine Dimesylate is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 07, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vyvanse (Lisdexamfetamine Dimesylate) is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Lead Product(s): Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Vyvanse
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 24, 2017

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lisdexamfetamine Dimesylate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vyvanse (Lisdexamfetamine Dimesylate) is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.
Product Name : Vyvanse
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 24, 2017

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 2592-19-0
End Use API : Lisdexamfetamine Dimesylate
About The Company : Suanfarma is a B2B life sciences company focused on developing, manufacturing, and distributing high-quality ingredients for the pharmaceutical industry in an i...
(4S,5R) -(-)-4-Methyl-5-phenyl-2-oxazolidinone
CAS Number : 16251-45-9
End Use API : Lisdexamfetamine Dimesylate
About The Company : Anvitha Life Care Private Limited, founded in 2016 by Dr. T. Prakasam and a team of experienced scientists and technocrats with over 80 years of combined expert...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamin Orion Pharma
Dosage Form : Capsule
Dosage Strength : 20mg
Packaging :
Approval Date : 04/01/2024
Application Number : 20221130000140
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamin Orion Pharma
Dosage Form : Capsule
Dosage Strength : 50mg
Packaging :
Approval Date : 04/01/2024
Application Number : 20221130000171
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamine Orion
Dosage Form : Capsule
Dosage Strength : 20mg
Packaging :
Approval Date : 30/01/2023
Application Number : 20210831000115
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamine Orion
Dosage Form : Capsule
Dosage Strength : 30mg
Packaging :
Approval Date : 30/01/2023
Application Number : 20210831000122
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamine Orion
Dosage Form : Capsule
Dosage Strength : 50mg
Packaging :
Approval Date : 30/01/2023
Application Number : 20210831000146
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Lisdexamfetamine Orion
Dosage Form : Capsule
Dosage Strength : 60mg
Packaging :
Approval Date : 30/01/2023
Application Number : 20210831000153
Regulatory Info : Approved
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Lisdexamfetamindimesylate \"Orion Pharma\"
Dosage Form : Hard Capsules
Dosage Strength : 20mg
Packaging :
Approval Date : 15-04-2024
Application Number : 28106882422
Regulatory Info : Prescription
Registration Country : Denmark
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Lisdexamfetamine \"Orion\"
Dosage Form : Hard Capsules
Dosage Strength : 20mg
Packaging :
Approval Date : 24-05-2023
Application Number : 28106668921
Regulatory Info : Prescription
Registration Country : Denmark
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Lisdexamfetamindimesylate \"Orion Pharma\"
Dosage Form : Hard Capsules
Dosage Strength : 40mg
Packaging :
Approval Date : 15-04-2024
Application Number : 28106882622
Regulatory Info : Prescription
Registration Country : Denmark
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Lisdexamfetamine \"Orion\"
Dosage Form : Hard Capsules
Dosage Strength : 50mg
Packaging :
Approval Date : 24-05-2023
Application Number : 28106669221
Regulatory Info : Prescription
Registration Country : Denmark
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
Global Sales Information
Market Place
Reply
23 Jan 2026
Reply
03 Dec 2025
Reply
15 Aug 2025
Reply
06 Aug 2025
Reply
03 May 2025
Reply
03 Apr 2025
Reply
12 Feb 2025
Reply
25 Jan 2025
Reply
06 Jan 2025
Reply
23 Oct 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Lisdexamfetamine Dimesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lisdexamfetamine Dimesylate manufacturer or Lisdexamfetamine Dimesylate supplier.
PharmaCompass also assists you with knowing the Lisdexamfetamine Dimesylate API Price utilized in the formulation of products. Lisdexamfetamine Dimesylate API Price is not always fixed or binding as the Lisdexamfetamine Dimesylate Price is obtained through a variety of data sources. The Lisdexamfetamine Dimesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A elvanse manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of elvanse, including repackagers and relabelers. The FDA regulates elvanse manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. elvanse API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of elvanse manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A elvanse supplier is an individual or a company that provides elvanse active pharmaceutical ingredient (API) or elvanse finished formulations upon request. The elvanse suppliers may include elvanse API manufacturers, exporters, distributors and traders.
click here to find a list of elvanse suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A elvanse DMF (Drug Master File) is a document detailing the whole manufacturing process of elvanse active pharmaceutical ingredient (API) in detail. Different forms of elvanse DMFs exist exist since differing nations have different regulations, such as elvanse USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A elvanse DMF submitted to regulatory agencies in the US is known as a USDMF. elvanse USDMF includes data on elvanse's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The elvanse USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of elvanse suppliers with USDMF on PharmaCompass.
A elvanse written confirmation (elvanse WC) is an official document issued by a regulatory agency to a elvanse manufacturer, verifying that the manufacturing facility of a elvanse active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting elvanse APIs or elvanse finished pharmaceutical products to another nation, regulatory agencies frequently require a elvanse WC (written confirmation) as part of the regulatory process.
click here to find a list of elvanse suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing elvanse as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for elvanse API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture elvanse as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain elvanse and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a elvanse NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of elvanse suppliers with NDC on PharmaCompass.
elvanse Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of elvanse GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right elvanse GMP manufacturer or elvanse GMP API supplier for your needs.
A elvanse CoA (Certificate of Analysis) is a formal document that attests to elvanse's compliance with elvanse specifications and serves as a tool for batch-level quality control.
elvanse CoA mostly includes findings from lab analyses of a specific batch. For each elvanse CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
elvanse may be tested according to a variety of international standards, such as European Pharmacopoeia (elvanse EP), elvanse JP (Japanese Pharmacopeia) and the US Pharmacopoeia (elvanse USP).